Viatris outlines long-term financial targets 2020-2030

What happened: Viatris, a global healthcare company, outlined its long-term financial targets for 2020-2030, expecting 5-6% total revenue CAGR, 7-8% adjusted EBITDA CAGR, 9-10% adjusted EPS CAGR, and $3 billion in annual free cash flow by 2030. Separately, VivoPower began a share conversion program to reduce public float and align management with long-term shareholder interests. Viatris also announced positive Phase 3 results for VR-205, a drug candidate for primary immunoglobulin A nephropathy, and secured a ¥40 billion loan to support general business purposes.

Market impact: The pharmaceutical sector, particularly companies with promising drug pipelines and long-term growth prospects, may see increased interest from investors. Viatris' financial targets and positive clinical trial results could drive valuation repricing, benefiting shareholders. VivoPower's share conversion program may impact its stock liquidity and potentially boost its share price.

What to watch next: Viatris' Q2 2022 earnings report on August 4, 2022, will provide further insight into its financial performance and progress towards its long-term targets. Additionally, investors should monitor regulatory decisions for VR-205, with a potential approval or rejection in the coming months. For VivoPower, investors should keep an eye on its share price and trading volume following the completion of its share conversion program.